A technology transfer office based in the UK is currently looking for new investment opportunities in the life science space. The firm currently invests capital in companies based outside of its parent organization, and therefore anticipates investing in around eight companies by the end of 2013. They typically allocate between £20,000 and £20 million per firm. Because institutional shareholders back the firm, they have an evergreen structure, and can deploy capital as soon as a compelling opportunity is identified.
The office is currently most interested in firms in the biotech space, specifically investing in biotech therapeutic and diagnostic firms. They have no particular preference in terms of what indication the company’s product is targeting, and will invest in firms that have products targeting orphan indications.
Investing in both pre-revenue companies, and companies that have positive cash flow, the office will consider firms with products in the preclinical phase of development all the way through to firms that have a product on the market. They have no strict criteria in terms of revenue and EBITDA for cash flow positive companies.
Next Phase Newsletter 
Leave a comment